Cibus, Inc. Logo

Cibus, Inc.

Develops & licenses gene-edited, non-transgenic traits to the seed industry for resilient crops.

CBUS | US

Overview

Corporate Details

ISIN(s):
US13173L1070 (+1 more)
LEI:
Country:
United States of America
Address:
6455 NANCY RIDGE DRIVE, 92121 SAN DIEGO
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

Cibus, Inc. is an agricultural biotechnology company that develops and licenses plant traits to the seed industry. The company utilizes a proprietary, high-throughput precision gene-editing technology to create specific, value-added traits in a non-transgenic manner, significantly accelerating the development timeline compared to traditional breeding. Cibus focuses on creating more resilient and sustainable crops by developing traits that provide herbicide tolerance, disease resistance, and pest resistance. Its business model involves partnering with seed companies to integrate these traits into major crops like canola, soybean, and wheat, generating revenue through licensing agreements and royalties.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Cibus, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Cibus, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Cibus, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Keros Therapeutics, Inc. Logo
United States of America
KROS
Kura Oncology, Inc. Logo
Develops targeted precision medicines for high-need cancers like leukemia, head & neck, and lung cancer.
United States of America
KURA
Larimar Therapeutics, Inc. Logo
Clinical-stage biotech developing protein therapies for rare diseases like Friedreich's ataxia.
United States of America
LRMR
Lexaria Bioscience Corp. Logo
Biotech firm with patented technology improving oral drug delivery and absorption.
United States of America
LEXX
LigaChem Biosciences Inc. Logo
Advancing a next-gen ADC platform to develop innovative medicines for unmet needs.
South Korea
141080
Linical Co., Ltd. Logo
Global CRO providing full-service drug development support for biopharma companies.
Japan
2183
Lipigon Pharmaceuticals AB Logo
Develops novel drugs for lipid metabolism disorders to reduce cardiovascular disease risk.
Sweden
LPGO
Lipum AB Logo
Develops first-in-class antibody treatments for chronic inflammatory diseases like arthritis.
Sweden
LIPUM
LIXTE BIOTECHNOLOGY HOLDINGS, INC. Logo
Developing novel PP2A inhibitors to enhance cancer therapies and overcome treatment resistance.
United States of America
LIXT
United States of America
RENB

Talk to a Data Expert

Have a question? We'll get back to you promptly.